Clinical Trial Update: A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase II trial evaluating the combination of Trisenox (arsenic trioxide) and thalidomide in myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Thalomid (thalidomide)
• Trisenox (arsenic trioxide)

Snippet

Sponsor: Veeda Oncology | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED